Synthace
Synthace provides a cloud-based, no-code digital experiment platform that lets biologists design, automate, and run biological experiments across multiple liquid-handler brands, with Synthace DOE and ChatGPT integration enabling AI-ready data generation for global pharmaceutical and biotechnology customers.
- Company typePrivate
- Founded2011
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Synthace does
Synthace is a London-headquartered SaaS company, founded in 2011 as a spin-out of University College London, that builds a cloud-based digital experiment platform for life-sciences R&D. The platform provides biologists with a no-code graphical interface to design, automate, and execute biological experiments, translating workflows into liquid-handling instructions for instruments from Hamilton, Tecan, SPT Labtech, BioTek, Repligen, and Beckman Coulter. Its flagship add-on, Synthace DOE, brings adaptive Design of Experiments capabilities with Builder, Planner, Preview, Runner, Experiment Map, and Response Analysis modules, and a 2023 integration with OpenAI's ChatGPT enables natural-language experiment design. The platform also auto-captures raw and metadata with full DOE context, producing the high-dimensional, structured datasets positioned as inputs to downstream AI/ML applications.
Synthace monetizes primarily through annual enterprise subscriptions to the platform and its protocols, supplemented by professional services such as DOE and Automation Masterclass training and embedded Field Application Scientist support. Go-to-market is enterprise field sales targeting top global pharmaceutical and biotechnology companies, with proof-of-concept-led deployments, channel partnerships with five liquid-handler OEMs, and a 2025 listing on Microsoft Azure Marketplace. The company reported more than 225% ARR growth in FY2020 and expanded from four to eight of the world's top pharma customers by 2022, with multiple accounts at six-figure ARR.
The company is venture-backed (most recent disclosed round a $35M Series C in November 2021 led by Horizons Ventures and Sofinnova Partners), has 51-100 employees with a US regional headquarters in Boston, and operates under CEO Guy Levy-Yurista with Dr. Donald Deieso as Board Chair. Named customers include AstraZeneca, Oxford Biomedica, Ipsen, Charles River Laboratories, MSD/Merck, UCL, and Cambridge Consultants, spanning pharma, cell and gene therapy, CROs, diagnostics, and academic research.
Synthace firmographics
Firmographics- Name
- Synthace
- Legal name
- Synthace Limited
- Website
- https://synthace.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Synthace provides a cloud-based, no-code digital experiment platform that lets biologists design, automate, and run biological experiments across multiple liquid-handler brands, with Synthace DOE and ChatGPT integration enabling AI-ready data generation for global pharmaceutical and biotechnology customers.
- Ownership category
- akta.pro rank
Synthace industry classification
Industry- Product category
- Life Sciences R&D Software
- NAICS
- Software Publishers (5132), Software Publishers (513210), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC), Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines) (HLACAOAO)
Keywords
Where Synthace is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Synthace business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Software Platform Subscription: Cloud-based software platform for biological experimentation, likely sold as annual subscriptions to enterprise pharmaceutical and biotech customers.
- Protocols and Trusted Protocols: Pre-built, verified protocols for common biological experiments (ELISA, qPCR, purification, construct assembly) delivered as part of the platform.
- Training and On-Site Support: Specialist support services including DOE training course, Automation Masterclass, and on-site implementation support from field application scientists.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise platform with specialist support |
| Subscription | Annual | Training and education services |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels9 records
Synthace product offering
Product offeringCore offering
Synthace sells a cloud-based Life Sciences R&D Digital Experiment Platform (SaaS) that lets biologists design, automate, run, and analyze biological experiments without writing code. The platform translates experimental workflows into liquid-handling instructions for major lab robots (Hamilton, Tecan, SPT Labtech, BioTek, Beckman, Gilson, Repligen) and includes the Synthace DOE Design of Experiments module, in silico simulation, automated contextual data capture, and a ChatGPT integration, producing AI-ready high-dimensional datasets. It is sold as annual enterprise subscriptions to pharmaceutical, biotech, diagnostics, and academic customers, supplemented by specialist training and on-site implementation support.
Product overview
Synthace offers a cloud-based digital experiment platform for life science R&D, consisting of the core Synthace Platform as the central operating system for biology, complemented by specialized modules including Synthace DOE (Design of Experiments tool), Automated Multivariate Experiments, Assay Development, Media Optimization, and Miniaturized Purification services. The platform enables biologists to design, automate, and run experiments without coding, generating AI-ready high dimensional data. Additional offerings include training programs (DOE Training Course, DOE Masterclass, Automation Masterclass) and specialized features like the Cherry Picker for liquid transfer specification.
Differentiator
Problem solved
Functional benefit
Brands
- Synthace DOE: An adaptive Design of Experiments (DOE) solution enabling scientists to quickly and easily define, execute, and analyze experiments without the need for statistical software or expertise. Built specifically for biologists.
- Antha
Products and services
- Synthace Platform Cloud-based R&D software platform that enables biologists to design, automate, and run biological experiments without coding, translating workflows into liquid-handling instructions for multiple lab robots and generating high-dimensional, fully contextualized datasets for AI analysis. Sold on annual subscription to enterprise pharmaceutical, biotech, diagnostics, and academic customers.
- Synthace DOE Adaptive Design of Experiments software built specifically for biologists, enabling scientists to define, execute, and analyze experiments without statistical software expertise. Includes Builder (drag-and-drop DOE workflows), Planner (automatic calculations), Preview (in-silico simulation), Runner (one-click execution), Experiment Map, and Response Analysis (predictive modeling of outcomes).
- Miniaturized Purification Protocol and service offering for miniaturized protein purification optimization on Tecan instruments (including the Te-Chrom system), enabling time and cost savings in bioprocessing labs through smaller-scale purification workflows.
Quantifiable outcome
- Experimental throughput increased by over tenfold
- +6 more outcomes
Companies that use Synthace
Customer profileNamed customers10 records
Segments4 records
Ideal customer profiles3 records
Synthace technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration10 records
AI capability5 records
Feature8 records
Synthace partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered core and minor.
- Charles River LaboratoriescoreCollaboration announced at SLAS2026 for scalable design of experiments software. Partnership to provide enhanced assay solutions for the global pharmaceutical industry with more robust, faster and cost-effective assays.
- MicrosoftcorePartnership to bring Synthace platform to Microsoft Azure cloud infrastructure, enabling broader accessibility and integration with Azure services.
- TecancoreStrategic go-to-market partnership for purification optimization. Collaboration to accelerate purification optimization in process development through augmented lab automation using Te-Chrom system.
- SPT LabtechcoreGo-to-market partnership for assay execution. Partnership on VPS4B screening platform announced at SLAS2026.
- HamiltoncoreStrategic go-to-market partnership for automated experimentation on Hamilton liquid handling platforms.
- BioTekcoreStrategic go-to-market partnership for assay development and execution on BioTek instruments.
- RepligencoreStrategic go-to-market partnership for lab equipment integration.
- Oxford BioMedicacoreCollaboration on bioprocessing workflows for cell and gene therapy development. Joint work on Bioprocessing 4.0 report.
- Cell and Gene Therapy CatapultcoreCollaboration on flexible data and physical automation infrastructure for cell and gene therapy development. Joint work integrating in-line analytics with lab automation.
- Cambridge ConsultantsminorPartnership to unlock full potential of biology through joint development of automated workflows and optimization of qPCR assays.
- UCLminorUCL selected Synthace to help make digital, cloud-based lab work a reality, bridging gap between digital and physical spaces.
- IpsencorePartnership to accelerate novel therapeutic development through automation, combining biopharma expertise with integrative software.
- Pistoia AllianceminorSynthace rejoined the Pistoia Alliance to support development and adoption of standards and FAIR (findable, accessible, reusable and interoperable) working practices.
- Microsoft ResearchcoreCollaboration on programming biological systems research, changing the way research on programming biological systems is conducted.
- MSD (Merck)coreCollaboration to develop biomanufacturing platform for improved biologics manufacturing.
- Dow AgroSciencesminorCollaboration using Synthace platform for agricultural science applications.
Scale indicators12 records
Recent moves7 records
Expansion highlights5 records
Synthace competitors and assessment
Company assessmentDirect peers
- Benchling: Benchling is a cloud-based R&D platform for life sciences spanning ELN, LIMS, and registry functionality. It directly competes with Synthace for enterprise pharma and biotech R&D budgets, offering a broader platform that overlaps with Synthace's experiment-design and structured-data value proposition.
- Dotmatics: Dotmatics (acquired by Siemens) provides an R&D scientific platform including ELN, LIMS, and data visualization used by major pharma. It targets the same enterprise life sciences customer base as Synthace and competes for the scientific data management and experiment informatics wallet share.
- LabVantage: LabVantage is an enterprise LIMS and laboratory informatics platform widely deployed in pharma and biotech. It overlaps with Synthace in the lab data management and structured experiment capture space, particularly with regulated pharma customers.
- LabWare: LabWare provides LIMS and ELN software used by major pharmaceutical and biotech companies. As an established laboratory informatics vendor, it competes with Synthace for the same enterprise pharma R&D software budgets.
- TetraScience: TetraScience is a scientific data cloud platform that ingests instrument data and structures it for analytics and AI/ML use. It directly addresses the same 'AI-ready data' problem Synthace solves, serving biotech and pharma R&D customers with data lakehouse architectures.
- Genedata: Genedata provides scientific data management and analysis platforms for biopharma R&D, including screening, biologics, and biomarker workflows. It serves large pharma customers with similar experiment informatics needs to Synthace.
Emerging players
- IDBS: IDBS provides the Polar ELN and bioprocess data management solutions. IDBS is already a Synthace integration partner for the ELN workflow but competes in adjacent bioprocess data capture and structured experiment informatics for pharma customers.
- Scitara: Scitara offers a Scientific Integration Platform (SIP) for connecting lab instruments and software systems. It overlaps with Synthace's device-agnostic integration and structured data capture value proposition, particularly for pharma labs with diverse instrument fleets.
- LabArchives: LabArchives is an ELN platform widely adopted in academic and commercial life sciences research. It competes for the lab-notebook and structured experiment capture layer of the stack that Synthace also addresses.
Others
- Insitro: Insitro is an AI-driven drug discovery company that combines ML with high-throughput biology. While not a direct SaaS peer, it shares Synthace's thesis that AI in drug discovery requires structured, high-dimensional experimental data, making it an adjacent player in the same value chain.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Synthace social profiles
Digital presenceSynthace compliance and trust
Trust signalCompliance2 records
Synthace financial estimates
Financial estimateRevenue estimate
Valuation estimate
Synthace leadership team
Management profileNumber of profiles
Profiles9 records
Synthace funding detail
Funding detailFunding overview
Funding rounds13 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Synthace M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Synthace
What does Synthace do?
Synthace sells a cloud-based Life Sciences R&D Digital Experiment Platform (SaaS) that lets biologists design, automate, run, and analyze biological experiments without writing code. The platform translates experimental workflows into liquid-handling instructions for major lab robots (Hamilton, Tecan, SPT Labtech, BioTek, Beckman, Gilson, Repligen) and includes the Synthace DOE Design of Experiments module, in silico simulation, automated contextual data capture, and a ChatGPT integration, producing AI-ready high-dimensional datasets. It is sold as annual enterprise subscriptions to pharmaceutical, biotech, diagnostics, and academic customers, supplemented by specialist training and on-site implementation support.
Is Synthace a public or private company?
Synthace is a private company. It is classified as venture growth investor backed and is currently operating.
When was Synthace founded?
Synthace was founded in 2011. It employs 11 to 50 people.
Where is Synthace based?
Synthace is headquartered in London, United Kingdom, in the Europe region.
How does Synthace make money?
Three revenue lines are on record. Software Platform Subscription is the primary driver. The others are protocols and Trusted Protocols and training and On-Site Support.
Who are Synthace's main competitors?
Direct peers on record are Benchling, Dotmatics, LabVantage, LabWare, TetraScience and Genedata. Emerging players are IDBS, Scitara and LabArchives. Insitro is listed as an others.
Does Synthace have an API?
No public API is recorded for Synthace.
What industry is Synthace in?
Synthace's product category is Life Sciences R&D Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D). Its NAICS code is 5132 and its SIC code is 7372.